Literature DB >> 7995960

Regulation of cAMP-responsive enhancer binding proteins during cell cycle progression in T lymphocytes stimulated by IL-2.

N Feuerstein1, D Huang, S H Hinrichs, D J Orten, N Aiyar, M B Prystowsky.   

Abstract

IL-2 stimulates the proliferative response of various lymphoid cells. Previous studies showed an increase in intracellular levels of cAMP concomitant with an increase in phosphorylation of discrete proteins by protein kinase A at late G1 phase in mitogen-stimulated lymphocytes. Thus, experiments were undertaken to study nuclear proteins that bind to the cAMP-responsive enhancer (CRE) in cloned T lymphocytes stimulated with IL-2. With the use of a 32P-labeled CRE consensus sequence in a DNA binding gel mobility shift assay, we showed that IL-2 stimulation resulted in the induction of two major DNA-protein complexes at late G1/S during the cell cycle. This binding was competed in a dose-dependent manner by a nonlabeled CRE oligonucleotide but was not competed by a nonlabeled AP-1 oligonucleotide. Rapamycin, a potent immunosuppressant, which arrests IL-2-stimulated T lymphocytes at G1/S, inhibited the IL-2-induced CRE binding activities concomitantly with inhibition of DNA synthesis. By using specific Abs in a gel mobility shift assay, we identified two known CREB/ATF transcription factors in the IL-2-induced CRE complexes: the CRE binding factor (CREB), and ATF1. The induction of CREB binding by IL-2 was not associated with an increase in its abundance but was associated with a major increase in CREB phosphorylation that was particularly prominent at late G1/S. However, we found that G1/S progression induced by IL-2 was not associated with an increase in the intracellular levels of cAMP. These results suggest that 1) the transcription factors CREB and ATF1 and possibly other CRE binding proteins may have an important role in the modulation of specific gene expression at G1/S during cell cycle progression induced by IL-2. 2) The involvement of these CRE binding transcription factors in IL-2-stimulated cells is regulated via a mechanism that is not cAMP dependent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7995960

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  CD2 signalling induces phosphorylation of CREB in primary lymphocytes.

Authors:  D J Guyot; G C Newbound; M D Lairmore
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

Review 2.  Mechanisms of T-cell activation by human T-cell lymphotropic virus type I.

Authors:  P Höllsberg
Journal:  Microbiol Mol Biol Rev       Date:  1999-06       Impact factor: 11.056

3.  Expression of arthritis-causing HLA-B27 on Hela cells promotes induction of c-fos in response to in vitro invasion by Salmonella typhimurium.

Authors:  T Ikawa; M Ikeda; A Yamaguchi; W C Tsai; N Tamura; N Seta; M Trucksess; R B Raybourne; D T Yu
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

4.  Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis.

Authors:  B E Wilson; E Mochon; L M Boxer
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

5.  Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers.

Authors:  J Zhang; I Scordi; M J Smyth; M G Lichtenheld
Journal:  J Exp Med       Date:  1999-11-01       Impact factor: 14.307

6.  Targeting Overexpressed Activating Transcription Factor 1 (ATF1) Inhibits Proliferation and Migration and Enhances Sensitivity to Paclitaxel In Esophageal Cancer Cells.

Authors:  Qianyun Hao; Xuesong Zhao; Yi Zhang; Ziming Dong; Tao Hu; Ping Chen
Journal:  Med Sci Monit Basic Res       Date:  2017-09-15

7.  Cyclic AMP-Responsive Element-Binding Protein (CREB) is Critical in Autoimmunity by Promoting Th17 but Inhibiting Treg Cell Differentiation.

Authors:  Xiaohu Wang; Lu Ni; Dehui Chang; Huiping Lu; Yu Jiang; Byung-Seok Kim; Aibo Wang; Xindong Liu; Bo Zhong; Xuexian Yang; Chen Dong
Journal:  EBioMedicine       Date:  2017-10-12       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.